Skip to main content
OpenTrials
Completed

NCT Number: NCT04648852

The HUNT for Heart Failure" Risk Score

In this population study aim is to evaluate risk factors for heart failure and combine these into a new heart failure risk score.

Secondly, the heart failure risk score will be internally and externally validated, and compared with established heart failure risk scores. Additionally, the prevalence of heart failure as well as the distribution of the heart failure risk score in the general population will be evaluated.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Levanger hospital

Levanger, Norge, 7600, Norway

About this study

Explore which clinical risk factors or patient characteristics in a general population that are associated with increased risk for heart failure events and combine these into a new population-based heart failure risk score ("The HUNT for heart failure risk score") for predicting heart failure risk

Validate the newly developed heart failure risk score internally in the HUNT2 database

Compare the predictive ability of the new heart failure risk score with established heart failure risk scores (the ABC Health HF risk score, the Framingham HF risk score) and an established Norwegian cardiovascular risk score (NORRISK 2)

Estimate the prevalence of likely ("undiagnosed") heart failure , i.e., patients at high risk of HF, in a general population by using both the established heart failure risk scores and the newly developed heart failure risk score, and compare the heart failure event rate between those at high risk of heart failure and those with established heart failure.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participation in the third or second wave of the HUNT study

Exclusion criteria

  • Not willing to participate
  • Missing vital data

Treatment and study plan

Heart failure risk estimation

Other

Evaluation by heart failure risk score

Primary outcomes

  1. Time to incident heart failure event

    Time frame: 10 years

    Time to first heart failure hospitalization or heart failure related visit at the out-patient clinic (events defined according to the ESC 2016 heart failure guidelines)

Secondary outcomes

  1. Time to death from any cause

    Time frame: 10 years

    Time to death from any cause

  2. Time to first heart failure event or death from any cause

    Time frame: 10 years

    Time to first heart failure event (hospitalization or HF related visit at the out-patient clinic) or death from any cause

  3. Validity of heart failure risk score

    Time frame: 10 years

    Evaluation of the validity of heart failure risk score

Other outcomes

  1. Prevalence of heart failure

    Time frame: 0 days

    Prevalence of heart failure in a general population

  2. Distribution of heart failure risk score categories

    Time frame: 0 days

    Distribution of the heart failure risk score categories in a general population

Sponsors and collaborators

Lead sponsor

Helse Nord-Trøndelag HF

Other

Collaborators

  • Boehringer Ingelheim
  • Norwegian University of Science and Technology
  • Vestre Viken Hospital Trust

Registry information

Official study title

Heart Failure Burden and Heart Failure Risk in the General Population in Norway: "The HUNT for Heart Failure" Risk Score

Acronym: HUNT4HF

Important dates

Study start
2017
Primary completion
2023
Study completion
2023
First posted
Dec 2, 2020
Registry last updated
Jun 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.